HighMark Wealth Management LLC Purchases 45 Shares of Thermo Fisher Scientific Inc. $TMO

HighMark Wealth Management LLC boosted its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 140.6% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 77 shares of the medical research company’s stock after acquiring an additional 45 shares during the period. HighMark Wealth Management LLC’s holdings in Thermo Fisher Scientific were worth $31,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of TMO. Brighton Jones LLC lifted its holdings in shares of Thermo Fisher Scientific by 28.9% in the fourth quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company’s stock valued at $2,293,000 after purchasing an additional 988 shares in the last quarter. Revolve Wealth Partners LLC lifted its holdings in shares of Thermo Fisher Scientific by 4.2% in the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock valued at $255,000 after purchasing an additional 20 shares in the last quarter. RFG Advisory LLC lifted its holdings in shares of Thermo Fisher Scientific by 35.2% in the first quarter. RFG Advisory LLC now owns 4,735 shares of the medical research company’s stock valued at $2,356,000 after purchasing an additional 1,233 shares in the last quarter. Hennion & Walsh Asset Management Inc. lifted its holdings in shares of Thermo Fisher Scientific by 35.3% in the first quarter. Hennion & Walsh Asset Management Inc. now owns 6,354 shares of the medical research company’s stock valued at $3,162,000 after purchasing an additional 1,658 shares in the last quarter. Finally, Apella Capital LLC lifted its holdings in Thermo Fisher Scientific by 10.5% during the first quarter. Apella Capital LLC now owns 600 shares of the medical research company’s stock worth $272,000 after acquiring an additional 57 shares during the period. Institutional investors own 89.23% of the company’s stock.

Insider Activity

In other news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $500.96, for a total value of $5,009,600.00. Following the completion of the transaction, the chief executive officer directly owned 115,174 shares in the company, valued at approximately $57,697,567.04. The trade was a 7.99% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction on Friday, July 25th. The shares were sold at an average price of $479.98, for a total value of $191,992.00. Following the completion of the transaction, the executive vice president owned 22,367 shares of the company’s stock, valued at approximately $10,735,712.66. This trade represents a 1.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 30,066 shares of company stock worth $14,182,963. 0.33% of the stock is owned by corporate insiders.

Thermo Fisher Scientific Stock Performance

Shares of TMO opened at $525.07 on Friday. The firm has a market cap of $198.27 billion, a PE ratio of 30.37, a PEG ratio of 2.88 and a beta of 0.77. The stock’s fifty day moving average price is $481.27 and its two-hundred day moving average price is $447.60. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50. Thermo Fisher Scientific Inc. has a 1 year low of $385.46 and a 1 year high of $611.49.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.22 by $0.14. The firm had revenue of $10.86 billion for the quarter, compared to analyst estimates of $10.68 billion. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The business’s revenue was up 2.9% on a year-over-year basis. During the same period in the previous year, the company posted $5.37 earnings per share. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, equities research analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be given a $0.43 dividend. The ex-dividend date is Monday, September 15th. This represents a $1.72 annualized dividend and a dividend yield of 0.3%. Thermo Fisher Scientific’s payout ratio is 9.95%.

Wall Street Analyst Weigh In

A number of analysts recently commented on the company. William Blair assumed coverage on Thermo Fisher Scientific in a report on Monday, August 18th. They set an “outperform” rating on the stock. Royal Bank Of Canada set a $561.00 price target on Thermo Fisher Scientific and gave the stock an “outperform” rating in a report on Tuesday, September 2nd. Robert W. Baird lifted their price target on Thermo Fisher Scientific from $553.00 to $567.00 and gave the stock an “outperform” rating in a report on Thursday, July 24th. HSBC reiterated a “hold” rating and set a $510.00 price target on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Finally, Wall Street Zen lowered Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research note on Sunday, September 7th. Fifteen investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $585.37.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.